CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 70 enrolled
Drug / intervention
CD07805/47 gel 0.5%/CD07805/47 Vehicle +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01659853
NCT01659853Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Controlled, Double-masked, Crossover Design Study to Compare Efficacy and Assess Safety of CD07805/47 Gel 0.5% Applied Once Daily vs Azelaic Acid Gel 15% Applied Twice Daily in Subjects With Erythema of Rosacea

Galderma R&D·interventional·Posted Aug 8, 2012·Updated Aug 25, 2022

In Brief

A Phase 3 clinical trial evaluating CD07805/47 gel 0.5%/CD07805/47 Vehicle and azelaic acid gel 15% for Erythema and Rosacea. Completed, enrolled 70 participants across 4 sites.

Detailed Summary

The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel 0.5% applied topically once daily versus azelaic acid gel 15% applied topically twice daily in subjects with moderate to severe facial erythema of rosacea.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErythema, Rosacea
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 8, 2012
Enrollment StartSep 1, 2012
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 13.9 years ago

Interventions

CD07805/47 gel 0.5%/CD07805/47 Vehicledrug

To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle. During each treatment period (baseline to Day 15): CD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily

azelaic acid gel 15%drug

During each treatment period (baseline to Day 15): azelaic acid gel 15%, topical, twice daily